BIO Double Helix Sponsor
Sponsors

Company Profile

Immune Cell Therapy

Cancer
Vaccines

4737 S Kimbark Avenue
Chicago, IL 60615
USA
N/A 		Incorporated in 2004
2 Employees 		Privately Held

This Year's Highlights

  • ICT filed an IND application for the Phase I/II clinical trial for NSCLC in 2007, and has completed the additional study requested by the FDA following its initial review. Reapplication is anticipated in September 2007.
  • In collaboration, University of Pittsburgh Cancer Institute is the site for the Company's Non-Small Cell Lung Cancer clinical trial
  • The GMP facility at the University of Pittsburgh will be used as the production site of the vaccine

Anticipated Highlights

  • Begin clinical trial for non-small cell lung cancer in fourth quarter of 2007
  • Currently, ICT is in advanced negotiations with incubator for space to conduct its operations. The incubator expects to make an initial investment in ICT.

Corporate Mission

Treatment of cancer patients at the earliest possible stage of the disease increases the likelihood of success. Immune Cell Therapy was founded to develop new DNA-based vaccines that enables treatment of cancer patients with minmal residual disease remaining after primary therapy. The vaccines are autologous, i.e., they are prepared from the patient?s own cancer cells.

ICT's short term goal is to obtain sufficient clinical data confirming the safety and efficacy of its immunotherapeutic approach.

The Company has targeted the treatment of patients with non-small cell lung cancer for its initial clinical trial. However, ICT's core technology has general applicability as it can also be used in the treatment of patients with breast, head and neck, prostate and various other types of cancer. A second trial for patients with breast cancer is anticipated in 2008.